title: Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus.
abstract: Primary effusion lymphoma (PEL) is a recently recognized disease that occurs most often in immunosuppressed patients, either with human immunodeficiency virus (HIV) or in the posttransplantation setting, and it occasionally occurs in nonimmunosuppressed patients. Patients present with lymphomatous effusions in serous cavities--pleura, pericardium, or peritoneum--without any identifiable tumor mass. PEL rarely responds to systemic chemotherapy, and the prognosis is poor, with a median survival time of less than 6 months for most cohorts. A standard treatment for PEL has not yet been identified. We describe a patient with HIV-seronegative PEL who relapsed after combination chemotherapy and then underwent successful treatment with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). The treatment was well tolerated, and the patient has been in remission for 12 months after HDC and ASCT.
authors.affiliation: Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea.
authors.forename: Jong-Ho
authors.initials: JH
authors.lastname: Won
authors.forename: Seung-Hyo
authors.initials: SH
authors.lastname: Han
authors.forename: Sang-Byung
authors.initials: SB
authors.lastname: Bae
authors.forename: Chan-Kyu
authors.initials: CK
authors.lastname: Kim
authors.forename: Nam-Su
authors.initials: NS
authors.lastname: Lee
authors.forename: Kyu-Taeg
authors.initials: KT
authors.lastname: Lee
authors.forename: Sung-Kyu
authors.initials: SK
authors.lastname: Park
authors.forename: Dae-Sik
authors.initials: DS
authors.lastname: Hong
authors.forename: Dong-Wha
authors.initials: DW
authors.lastname: Lee
authors.forename: Hee-Sook
authors.initials: HS
authors.lastname: Park
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018572:Disease-Free Survival; D006679:HIV Seropositivity; D006338:Heart Neoplasms / Q000150:complications / Q000628:therapy*; D006801:Humans; D008223:Lymphoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010490:Pericardial Effusion / Q000150:complications / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous